AR100270A1 - Anticuerpos ang2 - Google Patents
Anticuerpos ang2Info
- Publication number
- AR100270A1 AR100270A1 ARP150101338A ARP150101338A AR100270A1 AR 100270 A1 AR100270 A1 AR 100270A1 AR P150101338 A ARP150101338 A AR P150101338A AR P150101338 A ARP150101338 A AR P150101338A AR 100270 A1 AR100270 A1 AR 100270A1
- Authority
- AR
- Argentina
- Prior art keywords
- ang2
- antibodies
- cancer
- growth factor
- vascular endothelial
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente se refiere a anticuerpos que se unen a angiopoyetina-2 humana (Ang2, por sus siglas en inglés), y pueden ser útiles para tratar cáncer solo y en combinación con inhibidores de la trayectoria de VEGF (factor de crecimiento endotelial vascular), especialmente cáncer accionado por VEGFR2 (receptor 2 del factor de crecimiento endotelial vascular) y Ang2, que incluyen cáncer gástrico, carcinoma hepatocelular, de ovario, colorrectal, y de mama. Célula; proceso para producir un anticuerpo; composición farmacéutica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462000253P | 2014-05-19 | 2014-05-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR100270A1 true AR100270A1 (es) | 2016-09-21 |
Family
ID=54537974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150101338A AR100270A1 (es) | 2014-05-19 | 2015-05-04 | Anticuerpos ang2 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9695241B2 (es) |
| EP (1) | EP3145544B1 (es) |
| JP (2) | JP6002354B1 (es) |
| KR (1) | KR101943724B1 (es) |
| CN (1) | CN106456755B (es) |
| AP (1) | AP2016009553A0 (es) |
| AR (1) | AR100270A1 (es) |
| AU (1) | AU2015264550B2 (es) |
| BR (1) | BR112016023718A2 (es) |
| CA (1) | CA2945152A1 (es) |
| CL (1) | CL2016002892A1 (es) |
| EA (1) | EA201691889A1 (es) |
| ES (1) | ES2756331T3 (es) |
| IL (1) | IL248145A0 (es) |
| MX (1) | MX2016015151A (es) |
| NZ (1) | NZ724877A (es) |
| PE (1) | PE20161404A1 (es) |
| PH (1) | PH12016502297A1 (es) |
| SG (1) | SG11201608418PA (es) |
| TN (1) | TN2016000442A1 (es) |
| TW (1) | TWI551610B (es) |
| WO (1) | WO2015179166A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202108832XA (en) * | 2019-02-25 | 2021-09-29 | Pharmabcine Inc | Anti-ang2 antibody and use thereof |
| TW202115112A (zh) * | 2019-06-27 | 2021-04-16 | 德商百靈佳殷格翰國際股份有限公司 | 抗-angpt2抗體 |
| JP2022552323A (ja) | 2019-10-15 | 2022-12-15 | イーライ リリー アンド カンパニー | 組換え操作された、リパーゼ／エステラーゼ欠損哺乳動物細胞株 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7138370B2 (en) * | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
| BRPI0518209A (pt) * | 2004-10-19 | 2008-11-04 | Amgen Inc | agentes de ligação especìficos à angiopoietina-2 |
| MX2007007484A (es) | 2004-12-21 | 2007-07-20 | Astrazeneca Ab | Anticuerpos dirigidos a angiopoyetina 2 y usos de los mismos. |
| EP2664346A1 (en) * | 2007-03-20 | 2013-11-20 | Eli Lilly And Co. | Anti-sclerostin antibodies |
| JP5596559B2 (ja) | 2008-01-28 | 2014-09-24 | メディミューン リミテッド | 安定化アンジオポエチン２抗体とその用途 |
| US8133979B2 (en) * | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
| JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| US9527925B2 (en) * | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| AR100271A1 (es) * | 2014-05-19 | 2016-09-21 | Lilly Co Eli | Compuestos de vegfr2 / ang2 |
-
2015
- 2015-05-04 AR ARP150101338A patent/AR100270A1/es unknown
- 2015-05-05 TW TW104114316A patent/TWI551610B/zh not_active IP Right Cessation
- 2015-05-12 JP JP2016515959A patent/JP6002354B1/ja active Active
- 2015-05-12 MX MX2016015151A patent/MX2016015151A/es unknown
- 2015-05-12 AP AP2016009553A patent/AP2016009553A0/en unknown
- 2015-05-12 BR BR112016023718A patent/BR112016023718A2/pt not_active IP Right Cessation
- 2015-05-12 WO PCT/US2015/030267 patent/WO2015179166A1/en active Application Filing
- 2015-05-12 SG SG11201608418PA patent/SG11201608418PA/en unknown
- 2015-05-12 AU AU2015264550A patent/AU2015264550B2/en not_active Ceased
- 2015-05-12 NZ NZ724877A patent/NZ724877A/en not_active IP Right Cessation
- 2015-05-12 KR KR1020167031991A patent/KR101943724B1/ko active IP Right Grant
- 2015-05-12 ES ES15796232T patent/ES2756331T3/es active Active
- 2015-05-12 TN TN2016000442A patent/TN2016000442A1/en unknown
- 2015-05-12 EA EA201691889A patent/EA201691889A1/ru unknown
- 2015-05-12 CN CN201580024095.3A patent/CN106456755B/zh active Active
- 2015-05-12 CA CA2945152A patent/CA2945152A1/en not_active Abandoned
- 2015-05-12 EP EP15796232.5A patent/EP3145544B1/en active Active
- 2015-05-12 US US14/709,514 patent/US9695241B2/en active Active
- 2015-05-12 PE PE2016002175A patent/PE20161404A1/es not_active Application Discontinuation
-
2016
- 2016-09-02 JP JP2016171737A patent/JP6231632B2/ja active Active
- 2016-09-29 IL IL248145A patent/IL248145A0/en unknown
- 2016-11-14 CL CL2016002892A patent/CL2016002892A1/es unknown
- 2016-11-17 PH PH12016502297A patent/PH12016502297A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016532633A (ja) | 2016-10-20 |
| EP3145544A4 (en) | 2017-12-27 |
| TWI551610B (zh) | 2016-10-01 |
| AP2016009553A0 (en) | 2016-11-30 |
| EA201691889A1 (ru) | 2017-04-28 |
| KR101943724B1 (ko) | 2019-01-29 |
| JP2017031166A (ja) | 2017-02-09 |
| PH12016502297A1 (en) | 2017-02-13 |
| NZ724877A (en) | 2018-02-23 |
| CA2945152A1 (en) | 2015-11-26 |
| EP3145544B1 (en) | 2019-10-09 |
| MX2016015151A (es) | 2017-03-07 |
| BR112016023718A2 (pt) | 2017-10-17 |
| TN2016000442A1 (en) | 2018-04-04 |
| JP6231632B2 (ja) | 2017-11-15 |
| JP6002354B1 (ja) | 2016-10-05 |
| SG11201608418PA (en) | 2016-11-29 |
| TW201605893A (zh) | 2016-02-16 |
| EP3145544A1 (en) | 2017-03-29 |
| KR20160145158A (ko) | 2016-12-19 |
| US9695241B2 (en) | 2017-07-04 |
| PE20161404A1 (es) | 2016-12-28 |
| CL2016002892A1 (es) | 2017-06-23 |
| CN106456755A (zh) | 2017-02-22 |
| CN106456755B (zh) | 2020-01-07 |
| WO2015179166A1 (en) | 2015-11-26 |
| IL248145A0 (en) | 2016-11-30 |
| AU2015264550A1 (en) | 2016-10-27 |
| US20150329627A1 (en) | 2015-11-19 |
| ES2756331T3 (es) | 2020-04-27 |
| AU2015264550B2 (en) | 2017-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20171383A1 (es) | Receptores de antigeno quimericos anti-dll3 y metodos de uso | |
| ECSP17011657A (es) | Conjugados de fármacos con anticuerpos anti-cdh6 | |
| PH12018500380A1 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
| CU20150128A7 (es) | Conjugados fármaco-anticuerpo | |
| NI201700001A (es) | Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas | |
| PE20170264A1 (es) | Anticuerpos monoclonales contra el epitope de her2 y sus metodos de uso | |
| PE20170704A1 (es) | Agente terapeutico que induce citotoxicidad | |
| MX2015012122A (es) | Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes. | |
| PH12017500406A1 (en) | Novel anti-mfi2 antibodies and methods of use | |
| BR112017009764A2 (pt) | anticorpos biespecíficos e métodos de uso em oftalmologia | |
| MX2018006249A (es) | Nuevos anticuerpos anti-emr2 y metodos de uso. | |
| CL2016001753A1 (es) | Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer | |
| AR103477A1 (es) | Compuestos de vegfa / ang2 | |
| AR100270A1 (es) | Anticuerpos ang2 | |
| MX2018007817A (es) | Nuevos anticuerpos anti-mmp16 y metodos para su uso. | |
| CO6690754A2 (es) | Composiciones de anticuerpo anti-vegfr-3 | |
| AR100271A1 (es) | Compuestos de vegfr2 / ang2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |